Actively Recruiting
Safety Evaluation of Intraparotid Injection of Bupivacaine with Dexamethasone During Partial Parotidectomy for Benign Tumors A Prospective Single-Center Study
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2026-09-10
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of injecting bupivacaine combined with dexamethasone directly into the parotid gland during partial parotidectomy surgery for benign tumors. This study focuses on preventing complications such as salivary fistulas, sialoceles, and other wound issues that can arise after surgery, which currently lack effective preventive methods. The trial is an early phase 1, single-center prospective cohort study sponsored by Centre Hospitalier Universitaire de Nmes. Participants receive an intraparotid injection of 20 ml of 0.5% bupivacaine and 0.5 ml of dexamethasone during surgery. This combination aims to block parasympathetic nerve fibers to reduce salivary secretions and postoperative complications, while also potentially improving pain control. The intervention is administered only once during the partial parotidectomy procedure. During the study, participants are monitored closely for local pain, neurological effects, allergic reactions, vital signs, and facial nerve function up to 15 days after injection. Additional assessments include postoperative pain measurements over the first 15 days and evaluation of wound healing complications. The study aims to assess tolerability and safety, with total participation lasting at least 15 days following surgery.
CONDITIONS
Brief Title
Clinical Tolerance of an Intraparotid Injection of Bupivacaine, Combined With Dexamethasone, After Parotidectomy for Benign Tumor
Research Team
B
Benjamin Lallemant
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here